[…] View from our meeting place! This past August 9th was the first official meeting of FSHD Israel, initiated by my 18-year-old daughter Hallel after we represented Israel in the first […]
First Meeting of FSHD Israel
Dyne ramps up its FSHD program
Dyne Therapeutics, a Waltham, Massachusetts, biopharmaceutical company, announced yesterday that it is accelerating its FSHD therapy development program. Here is their press release: Dyne to evaluate therapies targeting genetic cause […]
Recent FSHD research publications
[…] of DUX4, which is very important to understand if we are to attempt to treat FSHD by suppressing the unwanted negative effects of DUX4. * “Antisense Oligonucleotides Used to Target […]
BetterLife FSHD
A health & research platform providing tools to better understand and manage your FSHD Join BetterLife FSHD today! Join Here “This is a growing community that provides support and collects […]
Big pharmas show growing interest in FSHD
By June Kinoshita, FSHD Society The pharmaceutical industry is showing a growing interest in developing therapies for facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disorder affecting an estimated one million […]